Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 474

1.

Value of immunohistochemistry in the differential diagnosis of pleural sarcomatoid mesothelioma from lung sarcomatoid carcinoma.

Takeshima Y, Amatya VJ, Kushitani K, Kaneko M, Inai K.

Histopathology. 2009 May;54(6):667-76. doi: 10.1111/j.1365-2559.2009.03298.x.

PMID:
19438742
2.

Novel marker D2-40, combined with calretinin, CEA, and TTF-1: an optimal set of immunodiagnostic markers for pleural mesothelioma.

Mimura T, Ito A, Sakuma T, Ohbayashi C, Yoshimura M, Tsubota N, Okita Y, Okada M.

Cancer. 2007 Mar 1;109(5):933-8.

4.
5.

Sarcomatoid mesothelioma and its histological mimics: a comparative immunohistochemical study.

Lucas DR, Pass HI, Madan SK, Adsay NV, Wali A, Tabaczka P, Lonardo F.

Histopathology. 2003 Mar;42(3):270-9.

PMID:
12605647
6.

A comparative evaluation of immunohistochemical markers for the differential diagnosis of malignant pleural tumours.

Garcia-Prats MD, Ballestin C, Sotelo T, Lopez-Encuentra A, Mayordomo JI.

Histopathology. 1998 May;32(5):462-72.

PMID:
9639123
8.

Expression of calretinin and other mesothelioma-related markers in thymic carcinoma and thymoma.

Pan CC, Chen PC, Chou TY, Chiang H.

Hum Pathol. 2003 Nov;34(11):1155-62.

PMID:
14652817
10.

Primary thymic epithelial tumours of the pleura mimicking malignant mesothelioma.

Attanoos RL, Galateau-Salle F, Gibbs AR, Muller S, Ghandour F, Dojcinov SD.

Histopathology. 2002 Jul;41(1):42-9.

PMID:
12121236
11.

Is D2-40 a useful marker for distinguishing malignant mesothelioma from pulmonary adenocarcinoma and benign mesothelial proliferations?

Deniz H, Kibar Y, Güldür ME, Bakir K.

Pathol Res Pract. 2009;205(11):749-52. doi: 10.1016/j.prp.2009.06.001. Epub 2009 Jul 1.

PMID:
19573998
12.

The diagnostic utility of D2-40 for malignant mesothelioma versus pulmonary carcinoma with pleural involvement.

Saad RS, Lindner JL, Lin X, Liu YL, Silverman JF.

Diagn Cytopathol. 2006 Dec;34(12):801-6.

PMID:
17115439
13.

Immunohistochemical panels for differentiating epithelial malignant mesothelioma from lung adenocarcinoma: a study with logistic regression analysis.

Carella R, Deleonardi G, D'Errico A, Salerno A, Egarter-Vigl E, Seebacher C, Donazzan G, Grigioni WF.

Am J Surg Pathol. 2001 Jan;25(1):43-50.

PMID:
11145250
15.

Podoplanin is a better immunohistochemical marker for sarcomatoid mesothelioma than calretinin.

Padgett DM, Cathro HP, Wick MR, Mills SE.

Am J Surg Pathol. 2008 Jan;32(1):123-7.

PMID:
18162779
16.

Differential diagnosis of sarcomatoid mesothelioma from true sarcoma and sarcomatoid carcinoma using immunohistochemistry.

Kushitani K, Takeshima Y, Amatya VJ, Furonaka O, Sakatani A, Inai K.

Pathol Int. 2008 Feb;58(2):75-83. doi: 10.1111/j.1440-1827.2007.02193.x.

PMID:
18199156
18.
19.

Immunohistochemical analysis still has a limited role in the diagnosis of malignant mesothelioma. A study of thirteen antibodies.

Roberts F, Harper CM, Downie I, Burnett RA.

Am J Clin Pathol. 2001 Aug;116(2):253-62.

PMID:
11488073
20.

Glyco- and immunohistochemical refinement of the differential diagnosis between mesothelioma and metastatic carcinoma and survival analysis of patients.

Kayser K, Böhm G, Blum S, Beyer M, Zink S, André S, Gabius HJ.

J Pathol. 2001 Feb;193(2):175-80.

PMID:
11180163

Supplemental Content

Support Center